PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...

The EMA CHMP has determined that the proposed Artificial Intelligence-Based Measurement of Non-alcoholic Steatohepatitis Histology ... inclusion in clinical phase 2 and phase 3 trials in MASH ...

Theratechnologies Inc.’s THTX share price has surged by 28.57%, which has investors questioning if this is right time to sell ...

Table 1. Studies investigating the results of treatments through conventional light microscopy histology in human nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. FFA: Free fatty ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Experimentally, the expression of UCP-2 is upregulated in animal models of steatohepatitis ... Portal inflammation: none or mild. Grade 2, moderate Steatosis: any degree; usually mixed ...

which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California. As of March 7, ...

However, there are limited prospective data in well-characterised patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH ... as clinically apparent ascites requiring treatment, Grade ≥2 ...